NCT00967993View on ClinicalTrials.gov

Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
HyperphosphatemiaEnd-stage Renal DiseaseRenal Failure Chronic Requiring Hemodialysis
Interventions
DRUG

ferric citrate

KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate

Trial Locations (3)

70300

Assaf Haraofeh Medical Center, Ẕerifin

78306

Barzilai Medical Center Ben-Gurion University, Ashkelon

91120

Hadassah University Hospital-Ein Kerem, Jerusalem

Sponsors
All Listed Sponsors
lead

Keryx Biopharmaceuticals

INDUSTRY